Den Europæiske Union - dansk - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - hæmoragisk feber, ebola - vacciner - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svin - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

prevtec microbia gmbh - levende ikke-patogen escherichia coli o8: k87 - immunologicals for suidae, live bacterial vaccines, pig - svin - til aktiv immunisering af svin mod enterotoxigenic f4-positive escherichia coli med henblik på at:reducere forekomsten af moderat til svær post-fravænning escherichia coli-diarré (pwd) i svin, for at reducere den kolonisering af ileum og fækal udskillelse af enterotoxigenic f4-positive escherichia coli fra inficerede grise.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

elanco gmbh - levende ikke-patogen escherichia coli o141: k94 (f18ac) og o8: k87 (f4ac) - immunologicals for suidae, live bacterial vaccines - svin - til aktiv immunisering af svin fra 18 dage mod enterotoksigen f4-positiv og f18-positiv escherichia coli for at reducere forekomsten af ​​moderat til svær eftervænning e. coli diarré (pwd) hos smittede grise og for at reducere fækalt afgivelse af enterotoxigenisk f4-positiv og f18-positiv e. coli fra smittede grise.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ceva santé animale - inaktiveret coxiella burnetii vaccine, stamme nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - e. coli adhesin f4 (f4ab, f4ac, f4ad), e. coli adhesin f5, e. coli adhesin f6, e. coli adhesin f41 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - sows; sows (nullipar) - reduktion af neonatal enterotoxicosis af smågrise, der er forårsaget af e. coli-stammer, der udtrykker adhesinerne f4ab, f4ac, f4ad, f5, f6 og f41, i de første dage af livet.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

laboratorios hipra, s.a. - rekombinant verotoksin 2e af e. coli - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium, immunologicals for suidae - svin - aktiv immunisering af smågrise fra 2 dage gammel for at forhindre, at reducere dødelighed og kliniske tegn på ødem sygdomme (forårsaget af verotoksin 2e produceret af e. coli) og for at reducere tabet af daglig vægtforøgelse i efterbehandlingstiden i lyset af infektioner med verotoxin 2e-producerende e. coli indtil slagtning fra 164 dage.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - kylling - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid - meningitis, meningokok - vacciner - nimenrix er indiceret til aktiv immunisering af personer fra 6 uger mod invasive meningokoksygdomme forårsaget af neisseria meningitidis gruppe a, c, w-135 og y.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vacciner - profylakse af influenza forårsaget af a (h1n1) v 2009 virus. celvapan bør anvendes i overensstemmelse med officielle retningslinjer.